Fig. 3From: Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritisEstimated cumulative incidence of the discontinuation of tofacitinib and baricitinib treatment during the 24-week treatment periodBack to article page